Makoto Kuroda - Infectious Diseases

Author Information

Makoto Kuroda is a distinguished researcher affiliated with the Laboratory of Bacterial Genomics at the Pathogen Genomics Center, National Institute of Infectious Diseases in Tokyo, Japan. Kuroda's work primarily focuses on the genomics of pathogens, with a particular emphasis on infectious diseases and coronavirus research.

Research Contributions

Makoto Kuroda has made significant contributions to the field of infectious diseases, particularly in understanding the genetics and epidemiology of SARS-CoV-2, the virus responsible for COVID-19. Kuroda's research includes investigating the risks associated with activities such as singing in relation to COVID-19 spread, studying recombination between different SARS-CoV-2 variants, and exploring the long-term immunity and vaccine responses in animal models. These studies provide valuable insights into the behavior and evolution of the virus, as well as implications for public health strategies and vaccine development.

Aliases

Makoto Kuroda is also known by aliases such as M Kuroda and M. Kuroda in various publications and academic citations.

Publication and Citation Metrics

Metric	Value
Total Papers	327
Total Citations	15,183
H-Index	47

Publications:

Singing Is a Risk Factor for SARS-CoV-2 Infection: A Case-control Study of Karaoke-related COVID-19 Outbreaks in Two Cities in Hokkaido, Japan, Linked by Whole Genome Analysis

DOI: 10.1093/ofid/ofac158

Year: 2022

Recombination between SARS-CoV-2 omicron BA.1 and BA.2 variants identified in a traveller from Nepal at the airport quarantine Facility in Japan.

DOI: 10.1093/jtm/taac051

Year: 2022

Genome Recombination between Delta and Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

DOI: 10.7883/yoken.jjid.2021.844

Year: 2022

Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model

DOI: 10.1016/j.celrep.2022.110394

Year: 2022

A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.

DOI: 10.1126/sciadv.abh3827

Year: 2022

Correction to: Quick detection of causative bacteria in cases of acute cholangitis and cholecystitis using a multichannel gene autoanalyzer

DOI: 10.1007/s00595-022-02477-9

Year: 2022

Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3

DOI: 10.21203/RS.3.RS-318392/V1

Year: 2021

Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization

DOI: 10.1038/s42003-021-02128-8

Year: 2021

A discernable increase in the severe acute respiratory syndrome coronavirus 2 R.1 lineage carrying an E484K spike protein mutation in Japan

DOI: 10.1016/j.meegid.2021.105013

Year: 2021

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site

DOI: 10.1016/j.immuni.2021.08.025

Year: 2021

How Can Individuals Support CDC's Efforts?

Are There Any Side Effects?

What are the Achievements of the RBM Partnership?

How Can We Address Vaccine Hesitancy?

How Can Co-Infections Be Prevented?

What Role Do Surveillance Systems Play in Global Health?

How is Ebola Diagnosed?

How Does RT-PCR Work?

How Do Fungi Infect Hosts?

How Does Artemisinin Work?

Partnered Content Networks

Relevant Topics